Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04705025 · ClinicalTrials.gov registry record · NA

Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer

A NA study, sponsored by Jonsson Comprehensive Cancer Center.

Terminated
Registry status
NA
Development phase
5
Enrollment target

NCT04705025 is a NA study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04705025, a NA study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.

TERMINATED
Registry status
NA
Development phase
5 participants
Enrollment target

Study Summary

This phase II trial studies the effect of a digital application (app), BNT001, on cognitive-behavioral stress management in patients with stage I-III breast or lung cancer. The app is designed for cancer patients to treat anxiety and depressive symptoms related to their cancer diagnosis. The purpose of this study is to develop and refine procedures for eligibility screening, suicide risk assessment, and delivery of the app prior to the launch of a phase III randomized trial. The impact of the app in managing stress and improving quality of life and mood is a secondary aim.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • OTHER Interview
  • BEHAVIORAL Cognitive Behavior Therapy

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2021-04-08
Est. Completion 2023-03-30
Phase NA

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

What the Registry Record Tells You About NCT04705025

The ClinicalTrials.gov registry entry for NCT04705025 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04705025 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04705025 about?

NCT04705025 is a clinical study titled "Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer". This phase II trial studies the effect of a digital application (app), BNT001, on cognitive-behavioral stress management in patients with stage I-III breast or lung cancer. The app is designed for cancer patients to treat anxiety and depressive symptoms related to their cancer diagnosis. The purpose...

What is the current status of trial NCT04705025?

This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2021-04-08. Estimated completion is 2023-03-30.

What interventions are being tested in trial NCT04705025?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Interview (OTHER), Cognitive Behavior Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT04705025?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.